Swiss - Delayed Quote CHF

Molecular Partners AG (MOLN.SW)

Compare
4.5450
-0.0900
(-1.94%)
At close: January 10 at 5:30:32 PM GMT+1
Currency in CHF All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
6,002.0000
7,038.0000
189,556.0000
9,330.0000
9,344.0000
Operating Expense
69,073.0000
68,146.0000
72,943.0000
72,749.0000
67,670.0000
Operating Income
-63,071.0000
-61,108.0000
116,613.0000
-63,419.0000
-58,326.0000
Net Non Operating Interest Income Expense
3,826.0000
4,230.0000
523.0000
-457.0000
63.0000
Other Income Expense
-3,347.0000
-5,106.0000
717.0000
92.0000
-4,512.0000
Pretax Income
-62,591.0000
-61,984.0000
117,853.0000
-63,783.0000
-62,775.0000
Tax Provision
--
--
--
2.0000
-11.0000
Net Income Common Stockholders
-62,591.0000
-61,984.0000
117,853.0000
-63,785.0000
-62,764.0000
Diluted NI Available to Com Stockholders
-62,591.0000
-61,984.0000
117,853.0000
-63,785.0000
-62,764.0000
Basic EPS
-1.75
-1.89
3.63
-2.06
-2.51
Diluted EPS
-1.75
-1.89
3.54
-2.06
-2.51
Basic Average Shares
32,936.1440
32,770.6650
32,469.9570
31,005.1710
25,000.6520
Diluted Average Shares
32,936.1440
32,770.6650
33,265.5670
31,005.1710
25,000.6520
Total Operating Income as Reported
-63,071.0000
-61,108.0000
116,613.0000
-63,418.0000
-58,326.0000
Total Expenses
69,073.0000
68,146.0000
72,943.0000
72,749.0000
67,670.0000
Net Income from Continuing & Discontinued Operation
-62,591.0000
-61,984.0000
117,853.0000
-63,785.0000
-62,764.0000
Normalized Income
-59,244.0000
-56,878.0000
117,136.0000
-63,863.2644
-58,252.7906
Interest Income
3,867.0000
4,279.0000
1,142.0000
99.0000
367.0000
Interest Expense
27.0000
34.0000
605.0000
548.0000
295.0000
Net Interest Income
3,826.0000
4,230.0000
523.0000
-457.0000
63.0000
EBIT
-62,564.0000
-61,950.0000
118,458.0000
-63,235.0000
-62,480.0000
EBITDA
-60,163.0000
-59,530.0000
120,846.0000
-60,670.0000
-59,593.0000
Reconciled Depreciation
2,401.0000
2,420.0000
2,388.0000
2,565.0000
2,887.0000
Net Income from Continuing Operation Net Minority Interest
-62,591.0000
-61,984.0000
117,853.0000
-63,785.0000
-62,764.0000
Total Unusual Items Excluding Goodwill
-3,347.0000
-5,106.0000
717.0000
92.0000
-4,512.0000
Total Unusual Items
-3,347.0000
-5,106.0000
717.0000
92.0000
-4,512.0000
Normalized EBITDA
-56,816.0000
-54,424.0000
120,129.0000
-60,762.0000
-55,081.0000
Tax Rate for Calcs
--
--
--
0.0001
0.0000
Tax Effect of Unusual Items
--
--
--
13.7356
-0.7906
12/31/2020 - 3/3/2015

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

NWRN.SW Newron Pharmaceuticals S.p.A.
8.88
+1.72%
 
IDIA.SW Idorsia Ltd
0.7790
-1.77%
 
SANN.SW Santhera Pharmaceuticals Holding AG
13.68
-2.84%
 
EVE.SW Evolva Holding SA
1.1000
-5.58%
 
ORN.F Oryzon Genomics S.A.
1.5020
+2.18%
 
HQ1.MU Oruka Therapeutics Inc. R
18.60
0.00%
 
5KW.F SkinBioTherapeutics plc
0.1720
+1.18%
 
7IZ.MU Ziccum AB
0.0298
-29.72%
 
PH4.F CStone Pharmaceuticals
0.2640
-1.49%
 
4AJ0.SG Alk-Abello A/S
19.46
+0.46%